



## Olema Oncology to Present at Two Upcoming Investor Conferences

November 9, 2021

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that management will participate in two upcoming investor conferences in November.

Details for the company's participation are as follows:

- **Event:** Jefferies London Healthcare Conference  
**Date:** Tuesday, November 16, 2021  
**Time:** 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)  
**Format:** Live Fireside Chat
- **Event:** 4th Annual Evercore ISI HealthCONx Conference  
**Date:** Tuesday, November 30, 2021  
**Time:** 11:45 a.m. ET (8:45 a.m. PT)  
**Format:** Live Fireside Chat

Live webcasts of these presentations may be accessed under the Investors & Media section of Olema's website ( [www.olema.com](http://www.olema.com)) and will be archived for 14 days.

### About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.

### Contact:

Eva Stroynowski  
Vice President, Communications and Investor Relations  
[eva@olema.com](mailto:eva@olema.com)